Poster Session 1-15 B Cell Lymphoma: Basic

Fri. Oct 11, 2019 5:40 PM - 6:15 PM Poster (Tokyo International Forum, B2F Hall E)

Chair: Chisako Iriyama (Dept. Hemat., Fujita Health Univ., Toyoake, Japan)

+Add all to schedule

[PS1-15-1] Establishment and characterization of the new ABC-type DLBCL cell line TMD12

Toshikage Nagao, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Osamu Miura (Hematol., Tokyo Med. Dent. Univ., Tokyo, Japan)

[PS1-15-2] Genetic diagnosis of splenic B-cell lymphoma/leukemia, unclassifiable by next-generation sequencing

Kazuya Ishiguro¹, Yasushi Sasaki², Takeshi Niinuma¹, Tetsuyuki Igarashi³, Toru Takahashi³, Hiromu Suzuki¹ (1.Dept. Mol. Biol., Sapporo Med. Univ., Sch. Med. Sapporo, Japan, 2.Dept. Biol., Center Med. Edu., Sapporo Med. Univ. Sapporo, Japan, 3.Dept. Hematol., Tenshi Hosp. Sapporo, Japan)

[PS1-15-3] Bruton's tyrosine kinase mutation analysis in patients with ibrutinib-resistant mantle cell lymphoma

Ritsuko Seki¹, Youhei Mizunoe², Yoshitaka Yamasaki¹, Shuki Oya¹, Takayuki Nakamura¹, Satoshi Morishige¹, Maki Yamaguchi¹, Kazutoshi Aoyama¹, Fumihiko Mouri¹, Koichi Osaki¹, Takashi Okamura³, Koichi Ohshima⁴, Koji Nagafuji¹ (1.Hematol. and Oncol., Kurume Univ. School of Med., Japan, 2.Dep. of Medicine, Kurume Univ. School of Medicine., Fukuoka, Japan, 3.Center of Hematol. and Oncol. St Marys Hospital., Fukuoka, Japan, 4.Department of Pathology, Kurume Univ. School of Medicine., Japan)

[PS1-15-4] GNA12-MAD1L1 fusion gene resulting from del(7)(p22.2p22.3) in non-Hodgkin B-cell lymphoma cell lines

Yosuke Matsumoto¹, Yoshiaki Chinen², Yuji Shimura³, Hisao Nagoshi⁴, Ayako Muramatsu¹, Kodai Kuriyama¹, Muneo Oshiro¹, Yoshiko Hirakawa¹, Toshiki Iwai¹, Hitoji Uchiyama¹, Tomohiko Taki^5,6, Shigeo Horiike³, Junya Kuroda³, Masafumi Taniwaki⁶ (1.Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 2.Department of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan, 3.Division of Hematology, Kyoto Pref. Univ. Med., Kyoto, Japan, 4.Department of Hematology and Oncology, Hiroshima University, Hiroshima, Japan, 5.Kyorin University Faculty of Health Science, Tokyo, Japan, 6.Center Molecular Diagnostics Therapeutics, Kyoto Pref. Univ. Med., Kyoto, Japan)

[PS1-15-5] Strong nuclear PAX5 by immunohistochemistry in DLBCL carrying t(9;14)(p13;q32)/PAX5-IGH

Hitoshi Ohno^1,2, Takashi Akasaka¹, Gen Honjo³ (1.Department of Hematology, Tenri Hospital, Tenri, Japan, 2.Tenri Institute of Medical Research, Tenri, Japan, 3.Department of Diagnostic Surgical Pathology, Tenri Hospital, Tenri, Japan)

[PS1-15-6] Prognostic value of pre-treatment lymphocyte-to-monocyte ratio in DLBCL patients treated with RCHOP

Ee Leng Gan, Tee Chuan Ong, Sen Mui Tan, Jameela Sathar (Haematology, Hospital Ampang, Malaysia)

[PS1-15-7] The effectiveness of obinutuzumab retreatment in obinutuzumab direct cell death resistant models

Takaaki Fujimura, Yoriko Yamashita, Shigeki Yoshiura, Natsumi Kawasaki, Mirei Kohno, Kumiko Kondoh, Naoki Harada, Yasushi Yoshimura (Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan)